18298942. SYNTHETIC TRANSCRIPTION FACTORS simplified abstract (THE REGENTS OF THE UNIVERSITY OF CALIFORNIA)
Contents
- 1 SYNTHETIC TRANSCRIPTION FACTORS
- 1.1 Organization Name
- 1.2 Inventor(s)
- 1.3 SYNTHETIC TRANSCRIPTION FACTORS - A simplified explanation of the abstract
- 1.4 Simplified Explanation
- 1.5 Potential Applications
- 1.6 Problems Solved
- 1.7 Benefits
- 1.8 Potential Commercial Applications
- 1.9 Possible Prior Art
- 1.10 Unanswered Questions
- 1.11 Original Abstract Submitted
SYNTHETIC TRANSCRIPTION FACTORS
Organization Name
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
Inventor(s)
Niklas F. C. Hummel of San Francisco CA (US)
Patrick M. Shih of Berkeley CA (US)
SYNTHETIC TRANSCRIPTION FACTORS - A simplified explanation of the abstract
This abstract first appeared for US patent application 18298942 titled 'SYNTHETIC TRANSCRIPTION FACTORS
Simplified Explanation
The present invention provides for a synthetic transcription factor (TF) comprising (a) a DNA-binding domain of a transcription factor linked to (b) an effector domain, and (c) optionally a nuclear localization sequence (NLS). The present invention also provides for a nucleic acid encoding an effector domain of the present invention. The DNA-binding domain can be a deactivated RNA-guided nuclease variant of Cas9 (dCas9).
- Synthetic transcription factor with DNA-binding domain and effector domain
- Nucleic acid encoding effector domain available
- Optional nuclear localization sequence (NLS)
- DNA-binding domain can be deactivated Cas9 variant (dCas9)
Potential Applications
The technology can be used in gene regulation studies, gene editing, and synthetic biology applications.
Problems Solved
The synthetic transcription factor allows for precise control over gene expression and regulation.
Benefits
Enhanced precision in gene editing and regulation, potential for targeted therapies, and improved understanding of gene function.
Potential Commercial Applications
Potential commercial applications include biotechnology research, pharmaceutical development, and gene therapy.
Possible Prior Art
Prior art may include similar synthetic transcription factors with different effector domains or DNA-binding domains.
Unanswered Questions
1. What specific effector domains can be linked to the DNA-binding domain in this synthetic transcription factor? 2. Are there any limitations to the use of the nuclear localization sequence (NLS) in this technology?
Original Abstract Submitted
The present invention provides for a synthetic transcription factor (TF) comprising (a) a DNA-binding domain of a transcription factor linked to (b) an effector domain, and (c) optionanlly a nuclear localization sequence (NLS). The present invention provides for a nucleic acid encoding an effector domain of the present invention. The DNA-binding domain can be a deactivated RNA-guided nuclease variant of Cas9 (dCas9).
